<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anesthesia for patients with substance use disorder or acute intoxication
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anesthesia for patients with substance use disorder or acute intoxication
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anesthesia for patients with substance use disorder or acute intoxication
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Gould, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Larry Lindenbaum, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            W Kirke Rogers, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael F O'Connor, MD, FCCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Natalie F Holt, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 31, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H12885109">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common indication for surgery and anesthesia of an acutely intoxicated individual is trauma. Other types of surgical emergencies resulting from drug misuse include vascular dissection and hemorrhagic complications associated with certain stimulants.
        </p>
        <p>
         This topic reviews perioperative and anesthetic considerations for patients who are acutely intoxicated with one or multiple substances (eg, alcohol, opioids benzodiazepines, cannabinoids, cocaine, amphetamines, hallucinogens) or have a recent history of substance use disorder or dependency.
        </p>
        <p>
         Screening and management of chronic alcohol use disorder is discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/7805.html" rel="external">
          "Identification and management of unhealthy alcohol use in the perioperative period"
         </a>
         .)
        </p>
        <p>
         Specific challenges for management of acute pain in patients with chronic opioid use disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/121628.html" rel="external">
          "Management of acute pain in adults with opioid use disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">
          "Pain control in the critically ill adult patient", section on 'Tolerance, withdrawal, and hyperalgesia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1394165952">
         <span class="h1">
          SCREENING FOR SUBSTANCE USE DISORDER
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History
         </strong>
         – As part of the routine preanesthesia evaluation, we ask all conscious preoperative patients about a current or past history of alcohol and/or recreational drug use. Individuals often refer to misused or illicit substances by street names, and these sometimes don't contain the expected agent [
         <a href="#rid1">
          1
         </a>
         ]. Notably, acute intoxication is frequently associated with trauma, and multiple substances may be involved [
         <a href="#rid2">
          2
         </a>
         ]. In one study of &gt;10,000 traumatically injured patients, a urine drug screen revealed that nearly 60 percent tested positive for at least one substance that can be misused, while 12 percent tested positive for multiple substances [
         <a href="#rid3">
          3
         </a>
         ]. Patients presenting for certain case types such as bariatric surgery [
         <a href="#rid4">
          4
         </a>
         ], organ transplantation [
         <a href="#rid5">
          5
         </a>
         ], and certain cardiovascular procedures [
         <a href="#rid6">
          6,7
         </a>
         ] may also be statistically more likely to have a history of substance use disorder.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Since some patients may be hesitant to disclose their drug use due to fear of stigma or legal consequences, it is important to clearly explain the medical "need to know" to ensure safe perioperative care. Knowing common names of various street drugs is helpful in asking specific queries about particular drugs. Studies have suggested that patients are reasonably honest about their drug use when asked directly. For example, a study conducted in trauma patients in Colorado and Texas noted 80 percent agreement in self-reported use of any one drug compared with results of a standard urine toxicology screen. Furthermore, negative predictive values were 90 to 95 percent in this study (ie, nearly all patients who denied drug use tested negative on the urine toxicology screen) [
         <a href="#rid8">
          8
         </a>
         ]. In another study, 53 percent of trauma patients able and willing to respond to a routine drug use questionnaire who tested positive for cannabis on a toxicology screen had also self-reported their use [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Single-question screens for possible misuse of alcohol or other drugs have been well-validated in primary care and can be adopted for use in the preoperative period. For example, asking a patient, "Do you sometimes drink beer, wine, or other alcoholic beverages?" and following up a positive response with the question: "How many times in the past year have you had five or more drinks (four for women) in a day?". These two queries have a high sensitivity and specificity for identifying unhealthy alcohol use [
         <a href="#rid10">
          10
         </a>
         ]. Other sensitive and specific screening methods use a questionnaire that can be rapidly administered in a conscious patient to estimate alcohol use (eg, the Alcohol Use Disorders Identification Test [AUDIT] or Substance Use Brief Screening [SUBS] questionnaire)  (
         <a class="graphic graphic_table graphicRef109025" href="/z/d/graphic/109025.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef53246" href="/z/d/graphic/53246.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid11">
          11
         </a>
         ]. Similarly, high sensitivity and specificity for identifying misuse of other substances can be obtained with the question: "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?" and by adding the explanation: "For instance, because of the experience or feeling it caused" if asked to clarify the meaning of "nonmedical reasons" [
         <a href="#rid12">
          12
         </a>
         ]. A detailed discussion of screening tools for alcohol and other substance use disorders can be found separately. (See
         <a class="medical medical_review" href="/z/d/html/14843.html" rel="external">
          "Screening for unhealthy use of alcohol and other drugs in primary care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – A thorough physical exam may uncover clues regarding possible acute intoxication or chronic substance misuse. Signs suggesting acute intoxication may include otherwise unexplained tachycardia, diaphoresis, pupillary changes, agitation, or lethargy. Signs suggesting chronic substance use disorder include hypertrophic scarring over veins (track marks) or poor dentition.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Testing
         </strong>
         – For patients suspected to be acutely intoxicated, rapid urine screening tests are readily available at most hospitals for commonly misused substances including opioids (with a fentanyl-specific screen in some institutions), benzodiazepines, cocaine, tetrahydrocannabinol ([THC], the psychoactive substance in marijuana), amphetamines and similar agents, and certain hallucinogens. Typically, results are available within one hour. Details regarding testing for substance use disorders are available in separate topics. (See
         <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">
          "Testing for drugs of abuse (DOAs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Notably, the availability of a biochemical screen for alcohol and other drug intoxication does not reduce the value of directly asking patients about drug and alcohol use. One study reported that sensitivity and positive predictive values for a standard urine toxicology screen were quite poor, suggesting that a negative toxicology screen may not accurately recognize a patient who is a current drug user [
         <a href="#rid8">
          8
         </a>
         ]. Specific challenges in ordering and interpreting these tests include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Since insurance companies in some states are allowed to deny reimbursement for hospital care of injured patients if the injury resulted from alcohol and drug use, routine ordering screening tests may be disincentivized [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         False positives are possible with screening assays. For example, the hallucinogen phencyclidine (PCP) is structurally similar to compounds such as
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         (an over-the-counter cough suppressant). One study noted that the majority of positive screening results for phencyclidine could be explained by the ingestion of a drug other than PCP [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A true positive result does not mean an individual is acutely intoxicated. For example, the cannabis plant from which marijuana is made contains other compounds besides THC (eg, cannabidiol [CBD]), which is frequently used in legal consumer products. Many CBD products contain trace amounts of THC that can result in a positive result on a urine drug screening test. However, neither CBD nor trace amounts of THC would have any psychotropic or physiologic effects relevant to the patient’s anesthetic management.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Also, THC and other drugs can cause a positive test days after last ingestion when the patient is no longer intoxicated and has no residual effects relevant for anesthetic management. Another example is a urine screen for cocaine metabolites that may remain positive for up to three days after acute intoxication. Also, amphetamines may be sampled from urine for up to six days after last taking the drug [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H328952062">
         <span class="h1">
          SEDATIVES
         </span>
        </p>
        <p class="headingAnchor" id="H3408559507">
         <span class="h2">
          Alcohols
         </span>
        </p>
        <p class="headingAnchor" id="H4170193276">
         <span class="h3">
          Ethanol
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common acute intoxicant in trauma patients is the ethanol from fermented fruit or grains that causes the intoxicating effects of alcoholic beverages such as beer, wine, and spirits [
         <a href="#rid16">
          16
         </a>
         ]. Ethanol has an overall effect as a central nervous system (CNS) depressant; however, the initial dopamine surge that accompanies acute ethanol ingestion may result in presentation with agitation rather than sedation. Pathophysiologic changes that may affect intraoperative care of patients with ethanol intoxication are summarized in the table  (
         <a class="graphic graphic_table graphicRef112946" href="/z/d/graphic/112946.html" rel="external">
          table 3
         </a>
         ). Details regarding general management of patients with acute ethanol intoxication are discussed separately (see
         <a class="medical medical_review" href="/z/d/html/333.html" rel="external">
          "Ethanol intoxication in adults"
         </a>
         ). Also, severe withdrawal symptoms can occur. (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes"
         </a>
         .)
        </p>
        <p>
         Considerations for anesthetic management of patients with known or suspected alcohol misuse include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute intoxication
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For elective cases, surgery is delayed until the effects of acute intoxication are no longer present so that adequate informed consent can be obtained and to allow time for gastric emptying to occur. Alcohol is known to delay gastric emptying in a non-dose-dependent fashion [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For emergency cases, rapid sequence induction and intubation (RSII) should be employed to prevent aspiration pneumonitis since ethanol causes delayed gastric emptying [
         <a href="#rid17">
          17
         </a>
         ] and the stomach may be full of both ethanol and food. (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ethanol is a CNS depressant that alters the function of ion channels at several receptor sites including those for N-methyl-D-aspartate (NMDA), serotonin 5-hydroxytryptamine [5-HT
         <sub>
          3
         </sub>
         ], glycine, and gamma-aminobutyric acid (GABA
         <sub>
          A
         </sub>
         ) [
         <a href="#rid18">
          18,19
         </a>
         ]. During acute intoxication, dose requirements of anesthetic agents are decreased due to additive CNS depression, even in patients with chronic alcohol use disorder [
         <a href="#rid18">
          18
         </a>
         ]. For this reason, doses of induction agents such as
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         should be decreased or avoided, especially in patients with hypotension or shock. During maintenance of anesthesia, volatile agents are carefully titrated since the minimum alveolar concentration (MAC) requirements are typically lower than those for nonintoxicated patients [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic misuse
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         With chronic excessive consumption of ethanol, dose requirements for general anesthetics and adjuvant sedative and opioid agents may be increased in a patient who is not acutely intoxicated due to development of enzyme induction or cross-tolerance [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Longstanding alcoholism may lead to liver dysfunction. The following considerations are prudent:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Limit
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         use in patients with chronic alcohol use disorder due to the possibility of acute hepatic failure associated with even moderate therapeutic doses of acetaminophen [
         <a href="#rid18">
          18,22,23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/340.html" rel="external">
          "Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Titrate doses of neuromuscular blocking agents (NMBAs) to effect, with guidance using a peripheral nerve stimulator monitor. The onset, metabolism, and duration of action of NMBAs may be affected by liver insufficiency. (See
         <a class="medical medical_review" href="/z/d/html/91242.html" rel="external">
          "Anesthesia for the patient with liver disease", section on 'Neuromuscular blocking agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H619583464">
         <span class="h3">
          Ethylene glycol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ethylene glycol is a sweet-tasting, odorless substance found in antifreeze solutions. It may be ingested intentionally because of its sweet taste or for its intoxicating effects, which initially manifest as CNS depression similar to ethanol [
         <a href="#rid24">
          24
         </a>
         ]. However, ethylene glycol is metabolized by alcohol dehydrogenase (ADH) to glycolaldehyde, and then by aldehyde dehydrogenase to glycolic acid, which causes the metabolic acidosis of acute ethylene glycol poisoning. Further metabolism into oxalic acid occurs, which can accumulate in renal tissue. Severe cardiopulmonary and renal toxicity with elevated osmolar gap, profound metabolic acidosis, and acute kidney injury can occur hours or days after acute intoxication.
        </p>
        <p>
         Suspected or known ingestion of ethylene glycol should prompt thorough evaluation with laboratory studies including arterial blood gases and blood chemistries, as well as serum lactate, osmolality, and ethanol and ethylene glycol levels. A high osmolal or anion gap in the correct clinical context indicates ethylene glycol intoxication. The osmolal gap increases secondary to the initial accumulation of unionized alcohols, followed by an increase in the anion gap secondary to the formation of ionized metabolites. However, a normal/low osmolal gap or anion gap does not rule out ethylene alcohol intoxication. Details regarding general management of ethylene glycol poisoning are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/336.html" rel="external">
          "Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Regarding anesthetic considerations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dose requirements for anesthetic agents will likely be decreased similar to intoxication with ethanol or other CNS depressants. (See
         <a class="local">
          'Ethanol'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperventilation may be present as a physiologic response compensating for the severe metabolic acidosis that may occur with acute ethylene glycol poisoning. In most cases, it is prudent to continue hyperventilation during the perioperative period, and
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         is administered when necessary [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94164.html" rel="external">
          "Intraoperative management of shock in adults", section on 'Initial interventions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2294.html" rel="external">
          "Bicarbonate therapy in lactic acidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since ethylene glycol is very rapidly absorbed from the gastrointestinal tract, intraoperative attempts at orogastric-tube aspiration or gastric lavage do little to reduce the ethylene glycol load.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H621345158">
         <span class="h3">
          Methanol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methanol is a colorless, odorless, highly volatile chemical found in Sterno, windshield washer fluid, and homemade or adulterated alcohols. Intoxication may be achieved through ingestion, inhalation, or dermal absorption. Methanol is metabolized by ADH into a toxic metabolite, formic acid, that is responsible for the signs of methanol poisoning. Other than inebriation, these signs include headache, ataxia, and visual disturbances, which typically occur 6 to 24 hours following ingestion [
         <a href="#rid26">
          26
         </a>
         ]. Details regarding general management of methanol poisoning are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/336.html" rel="external">
          "Methanol and ethylene glycol poisoning: Pharmacology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Regarding anesthetic considerations, as with ethanol and other CNS depressants, dose requirements for anesthetic agents will likely be decreased. (See
         <a class="local">
          'Ethanol'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1714531762">
         <span class="h3">
          Isopropyl alcohol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Isopropyl alcohol, most commonly found in rubbing alcohol and hand sanitizers, is more potent than ethylene glycol or methanol. Unlike these other agents, isopropyl alcohol is a secondary alcohol that is metabolized to acetone and causes only mild acidemia. A key feature in isopropyl alcohol intoxication is an elevated osmolal gap with a normal anion gap. Therefore, if an elevated anion gap is noted in a surgical patient with known isopropyl alcohol intoxication, alternative explanations should be sought (eg, co-intoxication with another alcohol such as ethylene glycol or end-organ hypoperfusion causing lactic acidosis).
        </p>
        <p>
         Details regarding general management of isopropyl alcohol poisoning are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/334.html" rel="external">
          "Isopropyl alcohol poisoning"
         </a>
         .)
        </p>
        <p>
         Regarding anesthetic considerations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Isopropyl alcohol poisoning does not cause prolonged sedation since it is quickly metabolized to acetone. CNS depression peaks at approximately 30 minutes after ingestion [
         <a href="#rid27">
          27
         </a>
         ]. Therefore, dosing requirements for anesthetic agents should not be decreased unless emergency surgery is necessary immediately after ingestion or co-intoxicants were ingested.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Since isopropyl alcohol is very rapidly absorbed from the gastrointestinal tract, intraoperative aspiration via an orogastric-tube or gastric lavage is unlikely to be beneficial.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3830463097">
         <span class="h2">
          Cannabinoids
         </span>
        </p>
        <p class="headingAnchor" id="H3300315471">
         <span class="h3">
          Cannabis (marijuana)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Marijuana is a product of the plant
         <em>
          Cannabis sativa
         </em>
         containing substantial amounts of the potent psychoactive agent delta-9-tetrahydrocannabinol (THC). The prevalence of cannabis use disorder among surgical patients is estimated to be approximately 6 percent [
         <a href="#rid28">
          28,29
         </a>
         ]. Details regarding general management of acute intoxication with cannabis are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/97099.html" rel="external">
          "Cannabis (marijuana): Acute intoxication"
         </a>
         .)
        </p>
        <p>
         Use of cannabis or cannabinoids is increasingly common in patients presenting for surgery [
         <a href="#rid30">
          30
         </a>
         ]. Some centers routinely screen all patients for cannabis use before surgery [
         <a href="#rid30">
          30
         </a>
         ]. Perioperative considerations for management of patients with known or suspected cannabis use include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preoperative management – We agree with guidelines published by the American Society of Regional Anesthesia and Pain Medicine (ASRA) recommending that all patients reporting chronic use of cannabinoids should be counseled on the potential risks of continued perioperative use [
         <a href="#rid30">
          30
         </a>
         ]. Elective surgery is postponed in patients with altered mental status or impairment of decision-making capacity due to acute cannabis intoxication. Even in the absence of overt intoxication, a delay of at least two hours after smoking cannabis is recommended to avoid increased risk of myocardial infarction (MI) [
         <a href="#rid30">
          30-32
         </a>
         ]. For patients with recent consumption of cannabinoids via other routes of administration, risks are weighed against benefits of proceeding with elective surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Various legal consumer products contain components other than THC such as cannabidiol (CBD) that are derived from the cannabis plant. CBD and many other cannabis-derived compounds may cause somnolence, but are unlikely to cause significant psychotropic or physiologic changes relevant for anesthetic management. However, some formulations of CBD products contain contaminants such as
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         or synthetic cannabinoids, which can have adverse hemodynamic effects [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Synthetic cannabinoids'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anesthetic requirements – Some studies suggest that preoperative cannabis use is associated with increased tolerance to general anesthesia with
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ], sedation with
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         and other agents [
         <a href="#rid35">
          35,36
         </a>
         ], and increased postoperative opioid requirements [
         <a href="#rid37">
          37,38
         </a>
         ]. However, acutely high levels of cannabis may decrease the MAC value of inhalation agents [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiovascular effects
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute intoxication or recent use may increase risk of perioperative MI [
         <a href="#rid30">
          30-32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute intoxication with moderate doses of THC reduces parasympathetic activity with resultant tachycardia [
         <a href="#rid38">
          38,40
         </a>
         ]. Thus, anesthetic drugs that increase heart rate such as
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         are avoided or used with caution [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myocardial depression and peripheral vasodilation may also occur. Thus, doses of anesthetic agents with myocardial depressant effects (eg, volatile inhalation agents) are titrated to avoid hypotension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory effects
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cannabis can cause respiratory depression that is additive to the depressant effects of other anesthetic agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although the isolated compound THC itself causes bronchodilation, smoking or vaping marijuana may cause bronchospasm and exacerbation of underlying pulmonary disease such as asthma or bronchitis, as well as upper airway edema and resultant airway obstruction during laryngoscopy and endotracheal intubation [
         <a href="#rid38">
          38,41-43
         </a>
         ]. These risks are similar to those seen after smoking or vaping nicotine or inhaling other irritants, as described in separate topics:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/127216.html" rel="external">
          "Smoking or vaping: Perioperative management", section on 'Perioperative risks of smoking'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/127216.html" rel="external">
          "Smoking or vaping: Perioperative management", section on 'Perioperative risks of vaping'
         </a>
         .)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/122671.html" rel="external">
          "E-cigarette or vaping product use-associated lung injury (EVALI)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal effects
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although cannabis is used to treat refractory nausea and vomiting in selected patients (see
         <a class="medical medical_review" href="/z/d/html/97099.html" rel="external">
          "Cannabis (marijuana): Acute intoxication", section on 'Medicinal use'
         </a>
         ), rare patients with long-standing daily use of marijuana may present with cannabinoid hyperemesis syndrome (CHS). This syndrome is characterized by severe nausea, vomiting, abdominal pain, and possibly dehydration and/or electrolyte abnormalities (eg, metabolic alkalosis, hypokalemia) if episodes of nausea and vomiting are protracted. Since symptoms of CHS usually readily resolve within 24 to 48 hours after abstinence from marijuana [
         <a href="#rid44">
          44
         </a>
         ], elective surgery is delayed. For emergency procedures, RSII is employed to prevent aspiration pneumonitis (see
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia"
         </a>
         ). Also, close perioperative monitoring of electrolytes is prudent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postoperative management – If appropriate for the surgical procedure, multimodal analgesia incorporating regional analgesia is typically used for patients with acute cannabis intoxication or cannabis use disorder, and opioids are used as rescue medication [
         <a href="#rid30">
          30
         </a>
         ]. Postoperatively, patients who consume cannabis routinely should be monitored for cannabis withdrawal symptoms.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2738652666">
         <span class="h3">
          Synthetic cannabinoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Synthetic cannabinoids (eg, "spice", "K2") are artificially manufactured chemicals that affect the same receptors as THC and tend to produce similar psychoactive effects [
         <a href="#rid45">
          45
         </a>
         ]. These agents may be undetectable in routine serum and urine toxicology testing [
         <a href="#rid46">
          46
         </a>
         ]. Notably, manufacture and ingredients of synthetic cannabinoid products are not standardized. They are typically dissolved in either ethanol or acetone, and the resulting liquid is smoked in e-cigarettes, sprayed on plant material that is then smoked, or burned and inhaled as incense or potpourri. Details regarding general management of patients acutely intoxicated with synthetic cannabinoids are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">
          "Synthetic cannabinoids: Acute intoxication"
         </a>
         .)
        </p>
        <p>
         Anesthetic considerations in patients using synthetic cannabinoids include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiovascular, respiratory, and gastrointestinal effects are similar to those in cannabis use. (See
         <a class="local">
          'Cannabis (marijuana)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unlike cannabis, severe intoxication with synthetic cannabinoids may cause serious life-threatening toxicity including coma, seizures, severe or malignant hyperthermia, rhabdomyolysis, and acute kidney injury [
         <a href="#rid46">
          46,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">
          "Synthetic cannabinoids: Acute intoxication", section on 'Severe intoxication'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In rare cases, coagulopathy and prolonged international normalized ratio (INR) or prothrombin time has occurred, with severe bleeding unresponsive to administration of
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          phytonadione
         </a>
         (vitamin K) or fresh frozen plasma [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">
          "Synthetic cannabinoids: Acute intoxication", section on 'Life-threatening coagulopathy (brodifacoum adulteration)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H384066506">
         <span class="h2">
          Gamma hydroxybutyrate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gamma hydroxybutyrate (GHB) or its metabolic precursors (gamma butyrolactone and 1,4-butanediol [1,4-BD]) are CNS depressants used recreationally as an intoxicant. This agent is usually manufactured as a colorless, odorless liquid with a slightly salty taste. Since GHB lowers inhibitions and typically causes antegrade memory loss, it has been used surreptitiously as a date-rape drug to facilitate sexual assault. Details regarding intoxication with this agent are found in a separate topic (see
         <a class="medical medical_review" href="/z/d/html/307.html" rel="external">
          "Gamma hydroxybutyrate (GHB) intoxication"
         </a>
         ). Severe withdrawal symptoms can occur, similar to those noted with alcohol or benzodiazepine withdrawal [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/309.html" rel="external">
          "Gamma hydroxybutyrate (GHB) withdrawal and dependence"
         </a>
         .)
        </p>
        <p>
         Significant anesthetic implications for chronic users of GHB are unlikely if they are not acutely intoxicated. However, GHB is often ingested with other CNS depressants (eg, alcohol), which increases the likelihood of the following adverse effects:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduction of dose requirements for anesthetic agents
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory depression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures or coma in rare cases
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3232168618">
         <span class="h2">
          Benzodiazepines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Benzodiazepines bind GABA
         <sub>
          A
         </sub>
         receptors in the CNS and reduce the excitability of neurons. They are highly lipid-soluble agents with rapid onset of action. Typical indications for long-term prescription of benzodiazepines include insomnia, seizure disorders, anxiety or panic disorders, and treatment of muscle spasms. However, one report notes that benzodiazepines are the third most commonly misused illicit or prescription drug in the United States (approximately 2.2 percent of the population) [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">
          "Benzodiazepine use disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/314.html" rel="external">
          "Benzodiazepine poisoning"
         </a>
         .)
        </p>
        <p>
         Anesthetic considerations in patients taking a benzodiazepine include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute benzodiazepine use
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dose requirements for anesthetic agents will likely be decreased, similar to other CNS depressants.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although benzodiazepines use typically does not cause significant hemodynamic changes, administration may result in mild hypotension or myocardial depression, especially if opioids are coadministered [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory depression may be present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic benzodiazepine use
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dose requirements for general anesthetics and adjuvant sedative may be increased due to development of enzyme induction or cross-tolerance, similar to chronic ethanol use (see
         <a class="local">
          'Ethanol'
         </a>
         above). Also, postoperative opioid use and adverse events after surgery are more likely [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Nevertheless, we recommend continuing prescribed benzodiazepine medication during the perioperative period to avoid risk of withdrawal and because the anxiolytic effects are likely to be useful.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2377181003">
         <span class="h2">
          Opioids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Details regarding general management of patients with acute or chronic opioid use are discussed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">
          "Opioid use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Perioperative appropriate uses of opioids are discussed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">
          "Perioperative uses of intravenous opioids in adults: General considerations"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/130113.html" rel="external">
          "Perioperative uses of intravenous opioids: Specific agents"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/130312.html" rel="external">
          "Approach to the management of acute pain in adults", section on 'Opioids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Considerations for anesthetic management of patients with opioid use disorders include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute opioid intoxication
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Profound analgesia decreases dose requirements for anesthetic agents. In patients overdosing on a high-affinity opioid such as carfentanil, the opioid receptor antagonist
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         may be inadequate to achieve reliable and prolonged reversal of respiratory depression [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">
          "Perioperative uses of intravenous opioids in adults: General considerations", section on 'Acute opioid intoxication'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory depression is typically present.
        </p>
        <p>
        </p>
        <p>
         ●Chronic opioid use
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Opioid tolerance and/or opioid-induced hyperalgesia (OIH) may be present in chronic opioid users, making perioperative pain control difficult to achieve [
         <a href="#rid55">
          55,56
         </a>
         ]. Use of multimodal, opioid-sparing techniques is recommended. Options include continuous neuraxial or peripheral regional analgesia techniques, nonopioid analgesics such as
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 specific inhibitors, gabapentinoids, and/or adjuvant inhalation or intravenous agents with analgesic properties (eg,
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         ). Adjuvant intravenous agents are continued through the postoperative period. (See
         <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">
          "Perioperative uses of intravenous opioids in adults: General considerations", section on 'Chronic opioid use'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83726.html" rel="external">
          "Management of acute pain in the patient chronically using opioids for non-cancer pain", section on 'Options for pain management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Withdrawal symptoms can begin as soon as 6 to 18 hours after abstinence in chronic opioid users  (
         <a class="graphic graphic_table graphicRef81045" href="/z/d/graphic/81045.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef106994" href="/z/d/graphic/106994.html" rel="external">
          table 5
         </a>
         ). Even those enjoying good analgesic effect from neuraxial or regional anesthetic blockade will require maintenance administration of an opioid agent. For such patients, opioid agonists with high binding affinity for the mu opioid receptor (eg,
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">
          sufentanil
         </a>
         ) are typically preferred. (See
         <a class="medical medical_review" href="/z/d/html/306.html" rel="external">
          "Opioid withdrawal in the emergency setting"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Long-term use of heroin (or other injected drugs) often results in difficult vascular access due to severe scarring and sclerosis that renders usually accessible veins such as those in the antecubital fossa unusable [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Considerations for specific opioids and opioid antagonists
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Transdermal
         </strong>
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         <strong>
          patches
         </strong>
         – These patches typically need replacement every three days. However, transdermal absorption of fentanyl is affected by skin temperature, and forced air warming devices over the patches may cause unexpectedly high uptake or overdose [
         <a href="#rid58">
          58
         </a>
         ]. Also, intraoperative fluid shifts may affect fentanyl distribution. Therefore, we remove fentanyl patches during surgery [
         <a href="#rid59">
          59
         </a>
         ]. However, transcutaneous fentanyl patches are replaced or an equivalent "basal" narcotic is administered in the early postoperative period to avoid risk of withdrawal symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          Buprenorphine
         </a>
         <strong>
          and buprenorphine/naloxone combinations
         </strong>
         – Buprenorphine is a long-acting partial opioid agonist that has an extremely high affinity for mu opioid receptors in the CNS, resulting in displacement of other opioid agonists from these receptors [
         <a href="#rid54">
          54,60
         </a>
         ]. Buprenorphine is also an antagonist at the kappa opioid receptor and is an agonist at the nociception protein receptor. The partial opioid agonism at the mu receptor minimizes risk of development of opioid withdrawal symptoms during abstinence from use of other opioids and prevents full development of respiratory depression, while acting together with nociception protein receptor activation to stimulate breathing [
         <a href="#rid54">
          54,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Formulations combining
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         with
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         are used to treat opioid use disorder. Notably, it may be extremely difficult to achieve adequate perioperative analgesia for patients taking this combination. Management of acute pain in such patients is discussed in detail in other topics. (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management", section on 'Buprenorphine: Opioid agonist'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121628.html" rel="external">
          "Management of acute pain in adults with opioid use disorder"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2975244948">
         <span class="h1">
          STIMULANTS
         </span>
        </p>
        <p class="headingAnchor" id="H517656894">
         <span class="h2">
          Cocaine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cocaine is a local anesthetic with potent vasoconstrictive properties that can be smoked, snorted, or injected. Acute cocaine use can cause hypertensive medical or surgical emergencies such as intracranial hemorrhage; stroke; seizure-related trauma; aortic dissection; arterial vasoconstriction or thrombus formation with subsequent myocardial, pulmonary, or peripheral arterial infarction; or ischemic bowel. (See
         <a class="medical medical_review" href="/z/d/html/303.html" rel="external">
          "Cocaine: Acute intoxication"
         </a>
         .)
        </p>
        <p>
         Considerations for anesthetic management of patients acutely intoxicated with cocaine include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe hypertension and cardiac dysrhythmias may be precipitated during laryngoscopy with endotracheal intubation or by noxious surgical stimuli [
         <a href="#rid41">
          41
         </a>
         ]. Prevention and/or treatment includes increasing anesthetic depth with intravenous or inhalation agents. Administration of vasodilators may be necessary (eg,
         <a class="drug drug_general" data-topicid="8528" href="/z/d/drug information/8528.html" rel="external">
          hydralazine
         </a>
         5 mg to 10 mg bolus doses or a continuous infusion of
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">
          nicardipine
         </a>
         , or
         <a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">
          clevidipine
         </a>
         for patients with persistent hypertension)  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid41">
          41,62
         </a>
         ]. However, beta-blockers (eg,
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         ) are relatively contraindicated due to risk of inducing unopposed alpha-adrenergic stimulation [
         <a href="#rid41">
          41,63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/303.html" rel="external">
          "Cocaine: Acute intoxication", section on 'Cardiovascular complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although increasing anesthetic depth may help mitigate hypertensive responses to noxious stimuli, overall anesthetic requirements are variable and may not be increased [
         <a href="#rid62">
          62,64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
         is avoided since it may potentiate cocaine's cardiovascular toxicity or cause myocardial depression if the patient has depleted catecholamine reserves due to hemorrhagic shock [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Disadvantages and adverse effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Drug-drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          Succinylcholine
         </a>
         is avoided when early postoperative extubation is planned. Plasma cholinesterase metabolizes both succinylcholine and cocaine; therefore, administration of succinylcholine may result in prolonged effects of cocaine as well as prolonged neuromuscular blockade [
         <a href="#rid41">
          41,66,67
         </a>
         ]. Furthermore, in patients who develop hyperthermia and rhabdomyolysis (see
         <a class="medical medical_review" href="/z/d/html/303.html" rel="external">
          "Cocaine: Acute intoxication", section on 'Other organ systems and complications'
         </a>
         ), succinylcholine may worsen hyperkalemia and cause life-threatening arrhythmias.
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          Rocuronium
         </a>
         is a reasonable alternative to produce a more reliable neuromuscular blockade. (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Alternatives to succinylcholine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe hyperthermia and rhabdomyolysis may occur [
         <a href="#rid68">
          68-72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/303.html" rel="external">
          "Cocaine: Acute intoxication", section on 'Other organ systems and complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This syndrome may be confused with malignant hyperthermia during anesthesia. (See
         <a class="medical medical_review" href="/z/d/html/401.html" rel="external">
          "Malignant hyperthermia: Diagnosis and management of acute crisis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3081545891">
         <span class="h2">
          Amphetamines and similar agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methamphetamine, amphetamine,
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         , and 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") have similar effects on the patient, although there are pharmacologic differences among these agents. Amphetamines and methylphenidate are readily available as prescription medications for attention deficit hyperactivity disorder. Methamphetamine is easily synthesized from over-the-counter medicines such as
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         and
         <a class="drug drug_general" data-topicid="9833" href="/z/d/drug information/9833.html" rel="external">
          pseudoephedrine
         </a>
         . The United States Department of Health and Human Services estimates that more than one million individuals use illicit methamphetamine each month, and an additional 1.5 million misuse stimulants such as amphetamine and methylphenidate [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
         Stimulation of alpha- and beta-adrenergic receptors is primarily responsible for the acute effects of these agents. Common symptoms include hyper-alertness, pupillary dilation, increased body temperature, diaphoresis, and severe tachycardia with or without increased blood pressure (BP) may be present. Details regarding management of acute intoxication from these agents are available in other topics. (See
         <a class="medical medical_review" href="/z/d/html/311.html" rel="external">
          "Methamphetamine: Acute intoxication"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">
          "Acute amphetamine and synthetic cathinone ("bath salt") intoxication"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/302.html" rel="external">
          "MDMA (ecstasy) intoxication"
         </a>
         .)
        </p>
        <p>
         Considerations for anesthetic management of patients acutely intoxicated with amphetamines include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolytes should be checked preoperatively and closely monitored throughout the perioperative period. Severe hyponatremia associated with cerebral edema and seizures may occur in users who have ingested excessive water to compensate for profound sweating. Overly rapid correction of marked hyponatremia can lead to central pontine myelinolysis (now referred to as osmotic demyelination syndrome ). Other electrolyte disturbances (eg, hypokalemia, hypermagnesemia, elevated anion gap acidosis) may also be present. Details regarding management of these abnormalities are discussed in separate topics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">
          "Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Electrolyte disturbances and other effects'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/302.html" rel="external">
          "MDMA (ecstasy) intoxication", section on 'Hyponatremia'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2317.html" rel="external">
          "Osmotic demyelination syndrome (ODS) and overly rapid correction of hyponatremia"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2287.html" rel="external">
          "Manifestations of hyponatremia and hypernatremia in adults", section on 'Osmolytes and cerebral adaptation to hyponatremia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe increases in heart rate and BP may occur. Due to potential for an exaggerated hypertensive response or life-threatening dysrhythmias, sympathomimetic drugs such as
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         are avoided or administered with extreme caution (eg, in small incremental doses of 2.5 mg to 5 mg). (See
         <a class="medical medical_review" href="/z/d/html/311.html" rel="external">
          "Methamphetamine: Acute intoxication", section on 'Hypertension'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/311.html" rel="external">
          "Methamphetamine: Acute intoxication", section on 'Tachycardia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">
          "Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Cardiovascular system'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/302.html" rel="external">
          "MDMA (ecstasy) intoxication", section on 'Cardiac effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe hyperthermia is possible and may be associated with rhabdomyolysis, disseminated intravascular coagulation, and hepatic and renal failure, as noted in separate topics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/311.html" rel="external">
          "Methamphetamine: Acute intoxication", section on 'Hyperthermia'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/302.html" rel="external">
          "MDMA (ecstasy) intoxication", section on 'Hyperthermia'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">
          "Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Hyperthermia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/82952.html" rel="external">
          "Acute amphetamine and synthetic cathinone ("bath salt") intoxication", section on 'Musculoskeletal system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This syndrome may be confused with malignant hyperthermia during anesthesia. (See
         <a class="medical medical_review" href="/z/d/html/401.html" rel="external">
          "Malignant hyperthermia: Diagnosis and management of acute crisis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overall anesthetic requirements are variable, but minimal alveolar concentration (MAC) requirements for volatile inhalation agents are typically decreased [
         <a href="#rid64">
          64,74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1804962344">
         <span class="h2">
          Hallucinogens and dissociative drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute intoxication with hallucinogens (eg, lysergic acid diethylamide [LSD], phencyclidine [PCP],
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , mescaline) can have physiologic effects similar to the amphetamine-like stimulants described above (see
         <a class="local">
          'Amphetamines and similar agents'
         </a>
         above); however, these effects are usually less severe. Details regarding management of acute intoxication with these agents are described in other topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/317.html" rel="external">
          "Intoxication from LSD and other common hallucinogens"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/313.html" rel="external">
          "Phencyclidine (PCP) intoxication in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/298.html" rel="external">
          "Ketamine poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Considerations for anesthetic management of acutely intoxicated patients include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LSD and PCP
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anesthetic requirements are variable, but MAC requirements for volatile inhalation agents are typically decreased [
         <a href="#rid64">
          64,74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         PCP or LSD intoxication may cause prolonged neuromuscular blocking effects after administration of
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         due to inhibition of plasma cholinesterase activity; thus, succinylcholine is avoided if early postoperative extubation is planned [
         <a href="#rid41">
          41
         </a>
         ].
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          Rocuronium
         </a>
         is a reasonable alternative, producing a more reliable neuromuscular blockade. (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Alternatives to succinylcholine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Although
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         causes little respiratory depression when appropriately used as a sedative-hypnotic anesthetic agent, higher "street" doses may cause respiratory depression [
         <a href="#rid75">
          75
         </a>
         ]. Also, there are synergistic anesthetic and respiratory depressant effects when ketamine is coadministered with a volatile inhalation anesthetic agent. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Ketamine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension may occur in patients taking chronically administered medications with noradrenergic effects such as amphetamines or norepinephrine reuptake inhibitors (eg, tricyclic antidepressants) [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Drug-drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4128173818">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/123018.html" rel="external">
          "Society guideline links: Alcohol consumption"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114306.html" rel="external">
          "Society guideline links: Alcohol use disorders and withdrawal"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114814.html" rel="external">
          "Society guideline links: Benzodiazepine use disorder and withdrawal"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114308.html" rel="external">
          "Society guideline links: Cannabis use disorder and withdrawal"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/134144.html" rel="external">
          "Society guideline links: Cocaine use and cocaine use disorder"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">
          "Society guideline links: Opioid use disorder and withdrawal"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115010.html" rel="external">
          "Society guideline links: Stimulant use disorder and withdrawal"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118165.html" rel="external">
          "Society guideline links: Substance misuse in pregnancy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4110133118">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preanesthesia screening
         </strong>
         – As part of the routine preanesthesia evaluation, we ask all conscious preoperative patients about a current or past history of alcohol and/or recreational drug use  (
         <a class="graphic graphic_table graphicRef109025" href="/z/d/graphic/109025.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef53246" href="/z/d/graphic/53246.html" rel="external">
          table 2
         </a>
         ). For patients suspected to be acutely intoxicated, rapid urine screening tests for opioids, benzodiazepines, cocaine, tetrahydrocannabinol (THC; the psychoactive substance in marijuana), amphetamines and similar agents, and certain hallucinogens are readily available at most hospitals. Although not always helpful, results are usually available within one hour. (See
         <a class="local">
          'Screening for substance use disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ethanol
         </strong>
         –  (
         <a class="graphic graphic_table graphicRef112946" href="/z/d/graphic/112946.html" rel="external">
          table 3
         </a>
         ) (see
         <a class="local">
          'Ethanol'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute intoxication
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For elective cases, delay surgery until the effects of acute intoxication are no longer present, and to allow time for gastric emptying to occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For emergency cases, we typically employ rapid sequence induction and intubation (RSII) to prevent aspiration pneumonitis since ethanol causes delayed gastric emptying of both alcohol and food.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Likely reduction in dose requirements for anesthetic agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic misuse
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Possible increases in dose requirements for general anesthetics and adjuvant sedative and opioid agents due to development of enzyme induction or cross-tolerance.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Liver insufficiency such that doses of neuromuscular blocking agents (NMBAs) should be titrated, and doses of
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         should be limited.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cannabinoids
         </strong>
         – Considerations for anesthetic management include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cannabis (marijuana)
         </strong>
         – (see
         <a class="local">
          'Cannabis (marijuana)'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Cardiovascular effects including tachycardia, myocardial depression, and peripheral vasodilation.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Respiratory effects including respiratory depression, as well as bronchospasm if marijuana is smoked or vaped.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Gastrointestinal effects including antiemetic effects in most patients. Rarely, development of cannabinoid hyperemesis syndrome (CHS) necessitates RSII to prevent aspiration pneumonitis, as well as close monitoring of electrolytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Synthetic cannabinoids
         </strong>
         – (see
         <a class="local">
          'Synthetic cannabinoids'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Cardiovascular, respiratory, and gastrointestinal effects similar to cannabis.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Unlike cannabis, serious life-threatening toxicity including coma, seizures, severe or malignant hyperthermia, rhabdomyolysis, and acute kidney injury that may occur with severe intoxication.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In rare cases, coagulopathy and severe bleeding unresponsive to
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         or fresh frozen plasma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gamma hydroxybutyrate
         </strong>
         – (see
         <a class="local">
          'Gamma hydroxybutyrate'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Likely reduction in dose requirements for anesthetic agents
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory depression
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Seizures or coma in rare cases
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benzodiazepines
         </strong>
         − (see
         <a class="local">
          'Benzodiazepines'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute use
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Decreased dose requirements for anesthetic agents
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Mild hypotension
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Respiratory depression
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic use
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Possible increase in dose requirements for general anesthetics and adjuvant sedative agents due to development of enzyme induction or cross-tolerance. Nevertheless, we continue any prescribed benzodiazepine medication during the perioperative period to alleviate anxiety and avoid withdrawal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opioids
         </strong>
         – (see
         <a class="local">
          'Opioids'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute intoxication
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Decreased dose requirements for anesthetic agents due to profound analgesia
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Respiratory depression
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chronic use
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Difficulties with perioperative pain control due to development of tolerance or opioid-induced hyperalgesia (OIH). We employ multimodal, opioid-sparing techniques. These may include continuous neuraxial or peripheral regional analgesia techniques, nonopioid analgesics such as
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         , nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase (COX)-2 specific inhibitors, gabapentinoids, and/or adjuvant inhalation or intravenous (IV) agents with analgesic properties (eg,
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Withdrawal symptoms, which can begin as soon as 6 to 18 hours after abstinence  (
         <a class="graphic graphic_table graphicRef81045" href="/z/d/graphic/81045.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef106994" href="/z/d/graphic/106994.html" rel="external">
          table 5
         </a>
         ). Opioid agonists with high binding affinity for the mu opioid receptor (eg,
         <a class="drug drug_general" data-topicid="8538" href="/z/d/drug information/8538.html" rel="external">
          hydromorphone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         ,
         <a class="drug drug_general" data-topicid="9954" href="/z/d/drug information/9954.html" rel="external">
          sufentanil
         </a>
         ) are typically preferred.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cocaine
         </strong>
         – (see
         <a class="local">
          'Cocaine'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe hypertension and cardiac dysrhythmias during laryngoscopy or noxious surgical stimuli. Prevention or treatment includes increasing anesthetic depth with IV or inhalation agents and/or administering vasodilators  (
         <a class="graphic graphic_table graphicRef119750" href="/z/d/graphic/119750.html" rel="external">
          table 6
         </a>
         ). Beta-blockers (eg,
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         ) are avoided to avoid unopposed alpha-adrenergic stimulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         which may potentiate cocaine's cardiovascular toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoid
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         if early postoperative extubation is planned since plasma cholinesterase metabolizes both succinylcholine and cocaine with prolongation of neuromuscular blockade. Also, hyperthermia and rhabdomyolysis may be exacerbated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe hyperthermia and rhabdomyolysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Amphetamines
         </strong>
         – (see
         <a class="local">
          'Amphetamines and similar agents'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum electrolytes are closely monitored since hyponatremia if excessive water was ingested to compensate for profound sweating. Other electrolyte disturbances (eg, hypokalemia, hypermagnesemia, elevated anion gap acidosis) may also be present.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe increases in heart rate and blood pressure. Avoid sympathomimetic drugs such as
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         (or administer with extreme caution) due to potential for an exaggerated hypertensive response or life-threatening dysrhythmias.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe hyperthermia and associated rhabdomyolysis, disseminated intravascular coagulation, and hepatic and renal failure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hallucinogens
         </strong>
         – (see
         <a class="local">
          'Hallucinogens and dissociative drugs'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lysergic acid diethylamide (LSD) and phencyclidine (PCP)
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Avoid
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         if early postoperative extubation is planned since plasma cholinesterase is inhibited by LSD or PCP.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          Ketamine
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Although
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         causes little respiratory depression when appropriately used as a sedative-hypnotic anesthetic agent, higher "street" doses and coadministration with other anesthetic agents may cause respiratory depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hypertension may occur in patients taking chronically administered medications with noradrenergic effects (eg, amphetamines or norepinephrine reuptake inhibitors such as tricyclic antidepressants).
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Griswold MK, Chai PR, Krotulski AJ, et al. Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose. Clin Toxicol (Phila) 2018; 56:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anitescu M. The patient with substance use disorder. Curr Opin Anaesthesiol 2019; 32:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheng V, Inaba K, Johnson M, et al. The impact of pre-injury controlled substance use on clinical outcomes after trauma. J Trauma Acute Care Surg 2016; 81:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudsi OY, Huskey K, Grove S, et al. Prevalence of preoperative alcohol abuse among patients seeking weight-loss surgery. Surg Endosc 2013; 27:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirri L, Potena L, Masetti M, et al. Prevalence of substance-related disorders in heart transplantation candidates. Transplant Proc 2007; 39:1970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh S, Trivedi A, Adhikari T, et al. Cocaine-related acute aortic dissection: patient demographics and clinical outcomes. Can J Cardiol 2007; 23:1131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daniel JC, Huynh TT, Zhou W, et al. Acute aortic dissection associated with use of cocaine. J Vasc Surg 2007; 46:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salottolo K, McGuire E, Madayag R, et al. Validity between self-report and biochemical testing of cannabis and drugs among patients with traumatic injury: brief report. J Cannabis Res 2022; 4:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Claudius IA, Jontz A, Levine M, et al. Marijuana self-report compared with testing in trauma patients before and after legalization. Clin Toxicol (Phila) 2020; 58:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med 2009; 24:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman R, Plaat F. Alcohol and anaesthesia. Contin Educ Anaesth Crit Care Pain 2009; 9:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med 2010; 170:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elkbuli A, Dowd B, Flores R, et al. Alcohol and Drug Testing in the National Trauma Data Bank: Does it Matter? J Emerg Trauma Shock 2019; 12:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krasowski MD, Pizon AF, Siam MG, et al. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med 2009; 9:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandevenne M, Vandenbussche H, Verstraete A. Detection time of drugs of abuse in urine. Acta Clin Belg 2000; 55:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetriades D, Gkiokas G, Velmahos GC, et al. Alcohol and illicit drugs in traumatic deaths: prevalence and association with type and severity of injuries. J Am Coll Surg 2004; 199:687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franke A, Nakchbandi IA, Schneider A, et al. The effect of ethanol and alcoholic beverages on gastric emptying of solid meals in humans. Alcohol Alcohol 2005; 40:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams C. Anaesthetic implications of acute and chronic alcohol abuse. S Afr J Anaesthesiol Analg 2010; 16:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aguayo LG, Peoples RW, Yeh HH, Yevenes GE. GABA(A) receptors as molecular sites of ethanol action. Direct or indirect actions? Curr Top Med Chem 2002; 2:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman R, Plaat F. Alcohol and anaesthesia. BJA Education 2009; 9:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spies CD, Rommelspacher H. Alcohol withdrawal in the surgical patient: prevention and treatment. Anesth Analg 1999; 88:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seeff LB, Cuccherini BA, Zimmerman HJ, et al. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Intern Med 1986; 104:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiødt FV, Rochling FA, Casey DL, Lee WM. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997; 337:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess R, Bartels MJ, Pottenger LH. Ethylene glycol: an estimate of tolerable levels of exposure based on a review of animal and human data. Arch Toxicol 2004; 78:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mirrakhimov AE, Ayach T, Barbaryan A, et al. The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions. Int J Nephrol 2017; 2017:7831358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraut JA, Mullins ME. Toxic Alcohols. N Engl J Med 2018; 378:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slaughter RJ, Mason RW, Beasley DM, et al. Isopropanol poisoning. Clin Toxicol (Phila) 2014; 52:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mücke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2018; 3:CD012182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAfee J, Boehnke KF, Moser SM, et al. Perioperative cannabis use: a longitudinal study of associated clinical characteristics and surgical outcomes. Reg Anesth Pain Med 2021; 46:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah S, Schwenk ES, Sondekoppam RV, et al. ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Reg Anesth Pain Med 2023; 48:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goel A, McGuinness B, Jivraj NK, et al. Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries: A Retrospective Cohort Analysis. Anesthesiology 2020; 132:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel RS, Kamil SH, Bachu R, et al. Marijuana use and acute myocardial infarction: A systematic review of published cases in the literature. Trends Cardiovasc Med 2020; 30:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poklis JL, Mulder HA, Peace MR. The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids. Forensic Sci Int 2019; 294:e25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmen IC, Beach JP, Kaizer AM, Gumidyala R. The association between preoperative cannabis use and intraoperative inhaled anesthetic consumption: A retrospective study. J Clin Anesth 2020; 67:109980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imasogie N, Rose RV, Wilson A. High quantities: Evaluating the association between cannabis use and propofol anesthesia during endoscopy. PLoS One 2021; 16:e0248062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Twardowski MA, Link MM, Twardowski NM. Effects of Cannabis Use on Sedation Requirements for Endoscopic Procedures. J Am Osteopath Assoc 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aleissa MM, Ahern KL, Stern GM. Peri-operative opioid and sedation requirements in patients who use marijuana and are undergoing total knee or total hip arthroplasty: A retrospective study. J Clin Anesth 2020; 66:109953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander JC, Joshi GP. A review of the anesthetic implications of marijuana use. Proc (Bayl Univ Med Cent) 2019; 32:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller J, Plöchl W, Reiter B, et al. The effect of oral Δ-9-tetrahydrocannabinol on the minimal alveolar concentration of sevoflurane: A randomised, controlled, observer-blinded experimental study. Eur J Anaesthesiol 2021; 38:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beaconsfield P, Ginsburg J, Rainsbury R. Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med 1972; 287:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez M, Birnbach DJ, Van Zundert AA. Anesthetic management of the illicit-substance-using patient. Curr Opin Anaesthesiol 2005; 18:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Symons IE. Cannabis smoking and anaesthesia. Anaesthesia 2002; 57:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills PM, Penfold N. Cannabis abuse and anaesthesia. Anaesthesia 2003; 58:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards JR. Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department. J Emerg Med 2018; 54:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cooper ZD. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. Curr Psychiatry Rep 2016; 18:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kourouni I, Mourad B, Khouli H, et al. Critical Illness Secondary to Synthetic Cannabinoid Ingestion. JAMA Netw Open 2020; 3:e208516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 2016; 54:1.
          </a>
         </li>
         <li class="breakAll">
          Synthetic marijuana and potential risk for bleeding. Department of Veteran Affairs Pharmacy Benefits Management Services. https://www.pbm.va.gov/PBM/vacenterformedicationsafety/nationalpbmbulletin/Synthetic_Marijuana_Potential_Risk_for_Bleeding_NATIONAL_PBM_BULLETIN_FINAL_040518_with_disclaimer.pdf (Accessed on July 19, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004; 75:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend 2019; 200:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudreault P, Guay J, Thivierge RL, Verdy I. Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment. Drug Saf 1991; 6:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaulton TG, Wunsch H, Gaskins LJ, et al. Preoperative Sedative-hypnotic Medication Use and Adverse Postoperative Outcomes. Ann Surg 2021; 274:e108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigurdsson MI, Helgadottir S, Long TE, et al. Association Between Preoperative Opioid and Benzodiazepine Prescription Patterns and Mortality After Noncardiac Surgery. JAMA Surg 2019; 154:e191652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Schrier R, Dahan JDC, Boon M, et al. Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity. Anesthesiology 2022; 136:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vadivelu N, Mitra S, Kaye AD, Urman RD. Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient. Best Pract Res Clin Anaesthesiol 2014; 28:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pulley DD. Preoperative Evaluation of the Patient with Substance Use Disorder and Perioperative Considerations. Anesthesiol Clin 2016; 34:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darke S, Ross J, Kaye S. Physical injecting sites among injecting drug users in Sydney, Australia. Drug Alcohol Depend 2001; 62:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frölich MA, Giannotti A, Modell JH. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg 2001; 93:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richebé P, Beaulieu P. Perioperative pain management in the patient treated with opioids: continuing professional development. Can J Anaesth 2009; 56:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gudin J, Fudin J. A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain. Pain Ther 2020; 9:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward EN, Quaye AN, Wilens TE. Opioid Use Disorders: Perioperative Management of a Special Population. Anesth Analg 2018; 127:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moon TS, Gonzales MX, Sun JJ, et al. Recent cocaine use and the incidence of hemodynamic events during general anesthesia: A retrospective cohort study. J Clin Anesth 2019; 55:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001; 345:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kram B, Kram SJ, Sharpe ML, et al. Analgesia and Sedation Requirements in Mechanically Ventilated Trauma Patients With Acute, Preinjury Use of Cocaine and/or Amphetamines. Anesth Analg 2017; 124:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy JL Jr. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth 1993; 40:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jatlow P, Barash PG, Van Dyke C, et al. Cocaine and succinylcholine sensitivity: a new caution. Anesth Analg 1979; 58:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman RS, Henry GC, Wax PM, et al. Decreased plasma cholinesterase activity enhances cocaine toxicity in mice. J Pharmacol Exp Ther 1992; 263:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nolte KB. Rhabdomyolysis associated with cocaine abuse. Hum Pathol 1991; 22:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merigian KS, Roberts JR. Cocaine intoxication: hyperpyrexia, rhabdomyolysis and acute renal failure. J Toxicol Clin Toxicol 1987; 25:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kosten TR, Kleber HD. Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse 1988; 14:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singhal PC, Rubin RB, Peters A, et al. Rhabdomyolysis and acute renal failure associated with cocaine abuse. J Toxicol Clin Toxicol 1990; 28:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roth D, Alarcón FJ, Fernandez JA, et al. Acute rhabdomyolysis associated with cocaine intoxication. N Engl J Med 1988; 319:673.
          </a>
         </li>
         <li class="breakAll">
          Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf (Accessed on July 19, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bala N, Kaur G, Attri JP, et al. Psychiatric and anesthetic implications of substance abuse: Present scenario. Anesth Essays Res 2015; 9:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aroni F, Iacovidou N, Dontas I, et al. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. J Clin Pharmacol 2009; 49:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liebe T, Li S, Lord A, et al. Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial. Int J Neuropsychopharmacol 2017; 20:909.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139188 Version 7.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28681615" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30985340" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The patient with substance use disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27537515" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The impact of pre-injury controlled substance use on clinical outcomes after trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23052540" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevalence of preoperative alcohol abuse among patients seeking weight-loss surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17692668" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevalence of substance-related disorders in heart transplantation candidates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18060098" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cocaine-related acute aortic dissection: patient demographics and clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17826227" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acute aortic dissection associated with use of cocaine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35676744" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Validity between self-report and biochemical testing of cannabis and drugs among patients with traumatic injury: brief report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31760815" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Marijuana self-report compared with testing in trauma patients before and after legalization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19247718" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Primary care validation of a single-question alcohol screening test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Alcohol and anaesthesia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20625025" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A single-question screening test for drug use in primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31198274" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Alcohol and Drug Testing in the National Trauma Data Bank: Does it Matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19400959" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11484423" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Detection time of drugs of abuse in urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15501107" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Alcohol and illicit drugs in traumatic deaths: prevalence and association with type and severity of injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699055" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The effect of ethanol and alcoholic beverages on gastric emptying of solid meals in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Anaesthetic implications of acute and chronic alcohol abuse
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12171577" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : GABA(A) receptors as molecular sites of ethanol action. Direct or indirect actions?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Alcohol and anaesthesia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10195555" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Alcohol withdrawal in the surgical patient: prevention and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3511825" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329933" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Acetaminophen toxicity in an urban county hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15372138" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ethylene glycol: an estimate of tolerable levels of exposure based on a review of animal and human data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28932601" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The Role of Sodium Bicarbonate in the Management of Some Toxic Ingestions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29342392" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Toxic Alcohols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24815348" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Isopropanol poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29513392" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Cannabis-based medicines for chronic neuropathic pain in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33208521" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Perioperative cannabis use: a longitudinal study of associated clinical characteristics and surgical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36596580" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31789638" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries: A Retrospective Cohort Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31439383" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Marijuana use and acute myocardial infarction: A systematic review of published cases in the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30442388" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The unexpected identification of the cannabimimetic, 5F-ADB, and dextromethorphan in commercially available cannabidiol e-liquids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32653758" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The association between preoperative cannabis use and intraoperative inhaled anesthetic consumption: A retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33661987" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : High quantities: Evaluating the association between cannabis use and propofol anesthesia during endoscopy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30985870" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Effects of Cannabis Use on Sedation Requirements for Endoscopic Procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32619794" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Peri-operative opioid and sedation requirements in patients who use marijuana and are undergoing total knee or total hip arthroplasty: A retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31384188" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A review of the anesthetic implications of marijuana use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32833854" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The effect of oralΔ-9-tetrahydrocannabinol on the minimal alveolar concentration of sevoflurane: A randomised, controlled, observer-blinded experimental study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4402574" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Marihuana smoking. Cardiovascular effects in man and possible mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16534357" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anesthetic management of the illicit-substance-using patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12392470" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cannabis smoking and anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14616609" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cannabis abuse and anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29310960" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27074934" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32687586" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Critical Illness Secondary to Synthetic Cannabinoid Ingestion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26567470" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26567470" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15225884" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31121495" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The epidemiology of benzodiazepine misuse: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1888441" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31415004" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Preoperative Sedative-hypnotic Medication Use and Adverse Postoperative Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31215988" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Association Between Preoperative Opioid and Benzodiazepine Prescription Patterns and Mortality After Noncardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34958670" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24815969" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26927748" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Preoperative Evaluation of the Patient with Substance Use Disorder and Perioperative Considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11173170" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Physical injecting sites among injecting drug users in Sydney, Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11524334" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19888637" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Perioperative pain management in the patient treated with opioids: continuing professional development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31994020" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29847389" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Opioid Use Disorders: Perioperative Management of a Special Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30660093" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Recent cocaine use and the incidence of hemodynamic events during general anesthesia: A retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11484693" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cardiovascular complications of cocaine use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28098590" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Analgesia and Sedation Requirements in Mechanically Ventilated Trauma Patients With Acute, Preinjury Use of Cocaine and/or Amphetamines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8443855" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/572161" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Cocaine and succinylcholine sensitivity: a new caution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1432697" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Decreased plasma cholinesterase activity enhances cocaine toxicity in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1743698" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Rhabdomyolysis associated with cocaine abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3586084" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Cocaine intoxication: hyperpyrexia, rhabdomyolysis and acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3055940" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2231831" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Rhabdomyolysis and acute renal failure associated with cocaine abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3412385" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Acute rhabdomyolysis associated with cocaine intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3412385" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Acute rhabdomyolysis associated with cocaine intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26712964" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Psychiatric and anesthetic implications of substance abuse: Present scenario.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19546251" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29099972" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
